The company has not filed an annual or quarterly report since its Q1 FY2023 10-Q, filed May 11, 2023. Its latest SEC filing is a 15-12G from Nov 9, 2023.
10-Q for Q1 FY2023, filed May 11, 2023
The sections below describe the company as of the FY2022 annual report.
Sells ROLVEDON to treat chemotherapy-related low white blood cell counts and develops targeted cancer medicines for people with lung and other cancers.
10-K for FY2022, filed Mar 31, 2023ROLVEDON™ is a novel long-acting granulocyte colony-stimulating factor (“G-CSF”) for the treatment of chemotherapy-induced neutropenia. On…View ↗
Our product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Serious adverse…View ↗
ROLVEDON (eflapegrastim) is a novel long-acting G-CSF that employs a proprietary LAPSCOVERY™ technology designed to enhance the duration of…View ↗
Our clinical development program for poziotinib has been focused on previously treated locally or advanced metastatic NSCLC, first-line…View ↗
Spectrum sells ROLVEDON to pharmaceutical wholesalers and distributors for agreed prices; sales are counted when the product is physically delivered.
10-K for FY2022, filed Mar 31, 2023ROLVEDON became available for commercial sale and shipment to patients with a prescription in the U.S. in the fourth quarter of 2022. We…View ↗
$10.1M
10-K for FY2022, filed Apr 1, 2023
$10.1M ↗
Spectrum sells ROLVEDON through group purchasing organizations, wholesalers and specialty distributors, and directly to clinics and hospitals; wholesalers and distributors then sell to clinics, hospitals and federal healthcare programs.
10-K for FY2022, filed Mar 31, 2023
No. It lost $75.4M in FY2022.
10-K for FY2022, filed Apr 1, 2023
−$72.7MView ↗
10-K for FY2022, filed Apr 1, 2023
−$75.4MView ↗
10-K for FY2022, filed Apr 1, 2023
−$97.3MView ↗
10-Q for Q1 FY2023, filed May 12, 2023
−$5MView ↗
8-K, filed Aug 1, 2023
At the effective time of the Merger (the “Effective Time”), (1) each share of Common Stock issued and outstanding immediately prior to the…View ↗
From pipeline to sales
The earlier report described ROLONTIS as an investigational treatment and the portfolio as development-stage drugs; the latest describes ROLVEDON as approved and being sold, alongside product candidates.
10-K for FY2019, filed Mar 2, 2020 10-K for FY2022, filed Mar 31, 2023Our product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Serious adverse…View ↗
ROLVEDON (eflapegrastim) is a novel long-acting G-CSF that employs a proprietary LAPSCOVERY™ technology designed to enhance the duration of…View ↗
We submitted our BLA for ROLVEDON to the FDA on October 24, 2019. Our BLA was supported by data from two similarly designed Phase 3…View ↗
Competes with Amgen, Coherus BioSciences, Mylan Pharmaceuticals, Sandoz, Pfizer, AstraZeneca, Takeda Pharmaceutical, Rain Therapeutics, Janssen Research & Development, Taiho Pharmaceutical, Cullinan Oncology, Daiichi-Sankyo, Genentech, Gilead Sciences, Jiangsu Hengrui Pharmaceuticals, Novartis International, Fresenius Kabi, Amneal Pharmaceuticals, G1 Therapeutics, and BeyondSpring
10-K for FY2022, filed Mar 31, 2023Companies that have products on the market or in research and development that target the same indications as our in-development products…View ↗
Loading...
